Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers

BACKGROUND: This study aimed to correlate body mass index or biomarkers with the frequency of common adverse events (AEs) with subcutaneous IFN β-1a during treatment titration in patients with relapsing-remitting multiple sclerosis previously naïve to IFN β. METHODS: Eighty-four patients (66.3% fema...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Muñoz, Delicias, Escartín, Antonio, Dapena, Dolores, Coret, Francisco, Fernández-Uría, Dionisio, Pérez, Domingo, Casanova, Bonaventura, Guijarro-Castro, Cristina, Munteis, Elvira, del-Campo Amigo, María, Pego, Robustiano, Calles, Carmen, García-Rey, César, Monsalve, Nuria, Sánchez-Matienzo, David
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3710468/
https://ncbi.nlm.nih.gov/pubmed/23845043
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2377-13-82
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados